Tekmira Pharmaceuticals said this week that it has amended its licensing deal with Hana Biosciences for three non-RNAi chemotherapy drug candidates in a move that will eliminate future payments to former debt holders.
In 2006, Tekmira licensed the legacy products to Hana, which assumed all expenses associated with their development in exchange for milestones and royalties. Under the terms of the amended deal, Hana will make a $5.75 million payment to Tekmira, which has agreed to reduce certain future payments associated with the drugs.
Tekmira said it would transfer the money to former debt holders in order to eliminate future payments to these debt holders.